Urogen Pharma Company Profile (NASDAQ:URGN)

About Urogen Pharma (NASDAQ:URGN)

Urogen Pharma logoUrogen Pharma Ltd, formerly Theracoat Ltd, is an Israel-based clinical-stage biopharmaceutical company. It is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC). Its other clinical-stage drug candidates include Vesimune and BotuGel. Vesimune is a formulation of the toll-like receptor7 (TLR7) agonist Imiquimod for local intravesical delivery for the treatment of Carcinoma In-Situ. BotuGel is an intravesical sustained release formulation of botulinum toxin for Overactive Bladder (OAB) and Interstitial Cystitis (IC). Its platform technologies include: RTGel and Immunotherapy.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:URGN
  • CUSIP: N/A
  • Web: www.urogen.com
  • Market Cap: $355.67 million
  • Outstanding Shares: 13,009,000
Average Prices:
  • 50 Day Moving Avg: $29.80
  • 200 Day Moving Avg: $21.41
  • 52 Week Range: $13.01 - $33.77
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -9.46
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $17.55 million
  • Price / Sales: 20.27
  • Book Value: $5.69 per share
  • Price / Book: 4.80
  • EBITDA: ($1,430,000.00)
  • Current Ratio: 15.79%
  • Quick Ratio: 15.71%
  • Average Volume: 51,226 shs.
  • Short Ratio: 0.54

Frequently Asked Questions for Urogen Pharma (NASDAQ:URGN)

What is Urogen Pharma's stock symbol?

Urogen Pharma trades on the NASDAQ under the ticker symbol "URGN."

When will Urogen Pharma make its next earnings announcement?

Urogen Pharma is scheduled to release their next quarterly earnings announcement on Monday, November, 13th 2017. View Earnings Estimates for Urogen Pharma.

Where is Urogen Pharma's stock going? Where will Urogen Pharma's stock price be in 2017?

4 brokerages have issued 12-month target prices for Urogen Pharma's shares. Their forecasts range from $25.00 to $37.00. On average, they anticipate Urogen Pharma's share price to reach $31.33 in the next twelve months. View Analyst Ratings for Urogen Pharma.

Who are some of Urogen Pharma's key competitors?

Who are Urogen Pharma's key executives?

Urogen Pharma's management team includes the folowing people:

  • Arie S. Belldegrun, Chairman of the Board
  • Ron Bentsur, Chief Executive Officer, Director
  • Gary S. Titus, Chief Financial Officer
  • Gil Hakim, President - Israeli Operation
  • Chaim Hurvitz, Director
  • Ran Nussbaum, Director
  • Kathryn E. Falberg, Independent Director
  • Stuart Holden M.D., Independent Director
  • Pini Orbach Ph.D., Independent Director

When did Urogen Pharma IPO?

(URGN) raised $46 million in an initial public offering on Thursday, May 4th 2017. The company issued 3,500,000 shares at $12.00-$14.00 per share. Jefferies and Cowen and Company served as the underwriters for the IPO and Raymond James and Oppenheimer were co-managers.

When does the company's lock-up period expire?

Urogen Pharma's lock-up period expires on Tuesday, October 31st. Urogen Pharma had issued 4,473,373 shares in its initial public offering on May 4th. The total size of the offering was $58,153,849 based on an initial share price of $13.00. After the expiration of the company's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted.

Who owns Urogen Pharma stock?

Urogen Pharma's stock is owned by many different of retail and institutional investors. Top institutional investors include Shikiar Asset Management Inc. (0.16%). View Institutional Ownership Trends for Urogen Pharma.

Who bought Urogen Pharma stock? Who is buying Urogen Pharma stock?

Urogen Pharma's stock was acquired by a variety of institutional investors in the last quarter, including Shikiar Asset Management Inc.. View Insider Buying and Selling for Urogen Pharma.

How do I buy Urogen Pharma stock?

Shares of Urogen Pharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Urogen Pharma's stock price today?

One share of Urogen Pharma stock can currently be purchased for approximately $27.34.

MarketBeat Community Rating for Urogen Pharma (NASDAQ URGN)
Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  37 (Vote Outperform)
Underperform Votes:  38 (Vote Underperform)
Total Votes:  75
MarketBeat's community ratings are surveys of what our community members think about Urogen Pharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Urogen Pharma (NASDAQ:URGN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $31.33 (14.61% upside)
Consensus Price Target History for Urogen Pharma (NASDAQ:URGN)
Price Target History for Urogen Pharma (NASDAQ:URGN)
Analysts' Ratings History for Urogen Pharma (NASDAQ:URGN)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/9/2017Jefferies Group LLCBoost Price TargetBuy$27.00 -> $37.00N/AView Rating Details
8/14/2017Oppenheimer Holdings, Inc.Set Price TargetBuy$32.00HighView Rating Details
5/30/2017Raymond James Financial, Inc.Initiated CoverageOutperform -> Outperform$25.00HighView Rating Details
5/30/2017Cowen and CompanyInitiated CoverageOutperformHighView Rating Details
(Data available from 10/23/2015 forward)


Earnings History for Urogen Pharma (NASDAQ:URGN)
No earnings announcements for this company have been tracked by MarketBeat.com


Earnings Estimates for Urogen Pharma (NASDAQ:URGN)
2017 EPS Consensus Estimate: ($3.54)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($3.00)($1.81)($2.41)
Q2 20172($0.62)($0.58)($0.60)
Q3 20172$0.09$0.10$0.10
Q4 20172($0.64)($0.62)($0.63)
(Data provided by Zacks Investment Research)


Dividend History for Urogen Pharma (NASDAQ:URGN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Urogen Pharma (NASDAQ:URGN)
No insider trades for this company have been tracked by MarketBeat.com


Headline Trends for Urogen Pharma (NASDAQ:URGN)
Latest Headlines for Urogen Pharma (NASDAQ:URGN)
Loading headlines, please wait.



Urogen Pharma (URGN) Chart for Monday, October, 23, 2017

This page was last updated on 10/23/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.